These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 32438071)

  • 1. Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes.
    Mulder S; Perco P; Oxlund C; Mehdi UF; Hankemeier T; Jacobsen IA; Toto R; Heerspink HJL; Pena MJ
    Transl Res; 2020 Aug; 222():17-27. PubMed ID: 32438071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.
    Lindhardt M; Persson F; Oxlund C; Jacobsen IA; Zürbig P; Mischak H; Rossing P; Heerspink HJL
    Nephrol Dial Transplant; 2018 Feb; 33(2):296-303. PubMed ID: 28064163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
    Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
    Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.
    Kato S; Maruyama S; Makino H; Wada J; Ogawa D; Uzu T; Araki H; Koya D; Kanasaki K; Oiso Y; Goto M; Nishiyama A; Kobori H; Imai E; Ando M; Matsuo S
    Clin Exp Nephrol; 2015 Dec; 19(6):1098-106. PubMed ID: 25795029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
    Nielsen SE; Persson F; Frandsen E; Sugaya T; Hess G; Zdunek D; Shjoedt KJ; Parving HH; Rossing P
    Diabet Med; 2012 Aug; 29(8):e184-90. PubMed ID: 22268920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy.
    Chen Y; Liu P; Chen X; Li Y; Zhang F; Wang Y
    Am J Med Sci; 2018 May; 355(5):418-424. PubMed ID: 29753370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
    Heerspink HJL; Xie D; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Perkovic V; Rossing P; Parving HH; de Zeeuw D;
    J Am Soc Nephrol; 2021 Nov; 32(11):2900-2911. PubMed ID: 34551995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression levels of serum vasohibin-1 and other biomarkers in type 2 diabetes mellitus patients with different urinary albumin to creatinine ratios.
    Ren H; Shao Y; Ma X; Yang M; Liu Y; Wang Q
    J Diabetes Complications; 2019 Jul; 33(7):477-484. PubMed ID: 31097304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes.
    Oiwa A; Hiwatashi D; Takeda T; Miyamoto T; Kawata I; Koinuma M; Yamazaki M; Komatsu M
    J Clin Endocrinol Metab; 2023 Aug; 108(9):2203-2210. PubMed ID: 36916985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
    Ogawa S; Takeuchi K; Mori T; Nako K; Ito S
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):477-9. PubMed ID: 16700881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study.
    Rachmani R; Slavachevsky I; Amit M; Levi Z; Kedar Y; Berla M; Ravid M
    Diabet Med; 2004 May; 21(5):471-5. PubMed ID: 15089793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis.
    Hou J; Xiong W; Cao L; Wen X; Li A
    Clin Ther; 2015 Sep; 37(9):2086-2103.e10. PubMed ID: 26254276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients.
    Żyłka A; Dumnicka P; Kuśnierz-Cabala B; Gala-Błądzińska A; Ceranowicz P; Kucharz J; Ząbek-Adamska A; Maziarz B; Drożdż R; Kuźniewski M
    Mediators Inflamm; 2018; 2018():7659243. PubMed ID: 30158836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.
    Pena MJ; Heinzel A; Rossing P; Parving HH; Dallmann G; Rossing K; Andersen S; Mayer B; Heerspink HJ
    J Transl Med; 2016 Jul; 14(1):203. PubMed ID: 27378474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes.
    de Carvalho JA; Tatsch E; Hausen BS; Bollick YS; Moretto MB; Duarte T; Duarte MM; Londero SW; Premaor MO; Comim FV; Delanghe JR; Moresco RN
    Clin Biochem; 2016 Feb; 49(3):232-6. PubMed ID: 26519090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing albuminuria in spot morning samples from diabetic patients.
    Sampaio E; Delfino VD
    Arq Bras Endocrinol Metabol; 2008 Dec; 52(9):1482-8. PubMed ID: 19197457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Shen X; Zhang Z; Zhang X; Zhao J; Zhou X; Xu Q; Shang H; Dong J; Liao L
    Lipids Health Dis; 2016 Oct; 15(1):179. PubMed ID: 27733168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.